BPC
MIRM icon

Bryce Point Capital’s Mirum Pharmaceuticals MIRM Stock Holding History

Bryce Point Capital’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$463K Buy
+6,319
New +$402K 0.57% 119

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Bryce Point Capital's MIRM Position: Q3 2025 in Review

Bryce Point Capital opened a new position in Mirum Pharmaceuticals (MIRM) in Q3 2025: 6,319 shares worth $463K. The stake represents 0.57% of the portfolio and ranks #119 among its holdings.

272 funds tracked by Wall St. Rank hold MIRM as of Q3 2025.

  • Bryce Point Capital held 6,319 shares of Mirum Pharmaceuticals worth $463K as of Q3 2025.
  • Mirum Pharmaceuticals was a new Bryce Point Capital position in Q3 2025.
  • Mirum Pharmaceuticals made up 0.57% of Bryce Point Capital's portfolio in Q3 2025, its #119 holding.
  • 272 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q3 2025.

Based on Bryce Point Capital's 13F filing for Q3 2025, filed 6 Nov 2025.